102-02-3

Basic information

• Product Name: PHENYLBIGUANIDE
• Synonyms: phenyldiguanide;1-PHENYLBIGUANIDE;N-PHENYLIMINODICARBONIMIDIC-DIAMIDE;PHENYLBIGUANIDE;2-(N2-Phenylamidino)guanidine;1-phenyl-biguanid;n-phenyl-n’-guanylguanidine;p1426
• CAS NO: 102-02-3
• Molecular Formula: C₈H₁₁N₅
• Molecular Weight: 177.21
• EINECS: 202-998-5
• Product Categories: AgonistsOrganic Building Blocks;Guanidines;Neurotransmitters;Nitrogen Compounds;Serotonergics
• Mol File: 102-02-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 135-142 °C(lit.)
• Boiling Point: 299.13°C (rough estimate)
• Flash Point: 188.7°C
• Appearance: /
• Density: 1.2512 (rough estimate)
• Vapor Pressure: 3.08E-06mmHg at 25°C
• Refractive Index: 1.6900 (estimate)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: alcohol: freely soluble
• PKA: 10.76, 2.13(at 25℃)
• Merck: 14,7276
• CAS DataBase Reference: PHENYLBIGUANIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PHENYLBIGUANIDE(102-02-3)
• EPA Substance Registry System: PHENYLBIGUANIDE(102-02-3)

Safety Data

• WGK Germany: 3
• RTECS: DU2450000
• Hazardous Substances Data: 102-02-3(Hazardous Substances Data)

Usage

Uses

1-Phenylbiguanide is a 5-hydroxytryptamine receptor agonist.

Definition

ChEBI: A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a phenyl group.

General Description

1-Phenylbiguanide is a 5-hydroxytryptamine receptor agonist and increases extracellular dopamine release in rat nucleus accumbens in vivo. It serves as building block for synthesis of heterocyclic compounds.

Purification Methods

Crystallise the biguanide from water or toluene. [Beilstein 12 H 370, 12 I 236, 12 III 807.]

InChI:InChI=1/C8H11N5/c9-7(10)13-8(11)12-6-4-2-1-3-5-6/h1-5H,(H6,9,10,11,12,13)

Upstream product

• 110-86-1 pyridine 
• 628-13-7 pyridine hydrochloride 
• 62-53-3 aniline 
• 127099-85-8 N-Cyanoguanidine 
• 55-57-2 1-phenylbiguanide monohydrochloride 
• 103-72-0 phenyl isothiocyanate 
• 4484-20-2 aniline benzenesulfonate 
• 142-04-1 aniline hydrochloride 
• 15989-47-6 1-phenyl-3-guanylthiourea 

Downstream Products

• 91719-85-6 4-Anilino-6-amino-s-triazin-2-propionsaeure 
• 64432-68-4 2-(4-amino-6-anilino-[1,3,5]triazin-2-yl)-ethanol 
• 64432-65-1 N-(phenylcarbamimidoyl-carbamimidoyl)-β-alanine 
• 537-17-7 W 1191-2 
• 7426-35-9 2-amino-4-anilino-6-methyl-1,3,5-triazine 
• 1843-21-6 N-phenyl-2-benzothiazolamine 
• 18824-43-6 N-carbamimidoyl-N'-phenyl-urea 
• 99845-00-8 methyl 4-amino-6-(phenylamino)-1,3,5-triazine-2-carboxylate 
• 41282-85-3 N²,6-diphenyl-1,3,5-triazine-2,4-diamine 
• 102154-24-5 amino-anilino-[1,3,5]triazine-2-carboxylic acid amide 
• 100952-43-0 6-(amino-anilino-[1,3,5]triazin-2-yl)-hexanoic acid hydrazide 
• 100794-09-0 5-(amino-anilino-[1,3,5]triazin-2-yl)-valeric acid hydrazide 

Relevant articles and documents

-

-

NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE

Methods of treating diseases related to cGAS activation. Small molecule inhibitors of cGAS and pharmaceutical compositions and uses thereof in treating autoimmune diseases or inflammation.

Novel compounds having treatment of immune diseases and use therof

The present invention relates to a novel compound capable of effectively treating and preventing immune disease and to a use thereof. The novel compound of the present invention suppresses the production of inflammatory cytokines and increases activities of regulatory T cells having immune regulatory ability. In addition, the compound of the present invention controls over an excessive immune response by inhibiting the production of autoantibodies and differentiation of osteoclasts, thereby being able to be used for treating immune diseases induced by regulatory anomalies of various immune response such as autoimmune disease, inflammatory diseases, and transplant rejection.(a) Cell toxicity effect control(MTT assay)(AA) Normal mouse cell(b) Autoantibody production immune reaction control(c) Inflammatory cytokine production control(d) Inflammatory gene expression controlCOPYRIGHT KIPO 2016